Lifyorli plus nab-paclitaxel cleared for platinum-resistant ovarian cancer

What this means

Lifyorli blocks a stress hormone receptor that may help some ovarian cancers grow, and is given alongside the chemotherapy drug nab-paclitaxel. The FDA approved this combination for women whose ovarian cancer stopped responding to platinum-based chemo. This gives patients with hard-to-treat disease a new treatment option that could potentially slow cancer progression when other therapies fail.